Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal.

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Glp-1 Analogues Market OverviewThe Glp analogues market size is expected to be worth USD 606.3 billion by 2034.The target market was valued at USD 45.3 billion in 2024.The market is projected to grow ...

insulin resistance and oxidative stress—that GLP-1 based drugs can positively impact,” Greig says. Clearly, those mechanisms can extend well beyond diabetes control or weight loss promotion.

Lexaria Bioscience (LEXX) announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower ...

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide ... the tolerability and glycemic control efficacy findings from human study GLP-1-H24-3 (the "Study"), ...